111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
老年动脉粥样硬化急性心肌梗死患者血清中 PDCD4 和 ADAM10 的表达及其联合预测不良预后的价值
Authors Pei X, Cui F, Chen Y, Yang Z, Xie Z, Wen Y
Received 1 July 2025
Accepted for publication 15 October 2025
Published 2 December 2025 Volume 2025:20 Pages 2283—2292
DOI https://doi.org/10.2147/CIA.S550861
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Nandu Goswami
Xueliang Pei,1 Facai Cui,2 Yu Chen,3 Zhiyuan Yang,1 Zhouliang Xie,1 Yongjin Wen1
1Department of Cardiovascular Surgery, Fuwai Central China Cardiovascular Hospital, Zhengzhou, People’s Republic of China; 2Department of Clinical Laboratory, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China; 3Department of Pathology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
Correspondence: Xueliang Pei, Email m15515600510@163.com
Purpose: To investigate serum programmed cell death factor 4 (PDCD4) and a disintegrin and metalloproteinase 10 (ADAM10) expression in elderly patients with atherosclerotic acute myocardial infarction (AMI) and assess their prognostic value.
Methods: A retrospective analysis was conducted on 134 elderly patients with atherosclerotic AMI (disease group) and 110 healthy controls. Serum PDCD4 and ADAM10 levels were measured using ELISA. Based on prognosis, patients were divided into good prognosis (n=79) and poor prognosis groups (n=55). Clinical factors and biomarker levels were compared between groups. Logistic regression identified independent predictors of poor prognosis, and receiver operating characteristic (ROC) curves assessed predictive performance.
Results: Serum PDCD4 and ADAM10 levels were significantly higher in AMI patients compared with controls, and further elevated in the poor prognosis group (P< 0.05). Poor prognosis was also associated with older age, diabetes, STEMI, larger infarct size, anterior wall infarction, higher Killip class and GRACE score, elevated NT-proBNP and hs-CRP, and reduced LVEF (P< 0.05). Logistic regression confirmed elevated PDCD4 and ADAM10, diabetes, Killip class ≥II, GRACE score ≥ 140, STEMI, anterior infarction, NT-proBNP increase, and reduced LVEF as independent predictors of poor prognosis (P< 0.05). ROC analysis showed AUCs of 0.837 for PDCD4, 0.859 for ADAM10, and 0.931 for their combination, with the combined model outperforming either marker alone (P< 0.05).
Conclusion: Serum PDCD4 and ADAM10 are elevated in elderly atherosclerotic AMI patients and independently associated with poor prognosis. Combined detection may provide improved prognostic assessment, although further studies are warranted to validate these findings.
Keywords: PDCD4, ADAM10, elderly, atherosclerosis, acute myocardial infarction, prognosis
1Department of Cardiovascular Surgery, Fuwai Central China Cardiovascular Hospital, Zhengzhou, People’s Republic of China; 2Department of Clinical Laboratory, Henan Provincial People’s Hospital, Zhengzhou, People’s Republic of China; 3Department of Pathology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
Correspondence: Xueliang Pei, Email m15515600510@163.com
Purpose: To investigate serum programmed cell death factor 4 (PDCD4) and a disintegrin and metalloproteinase 10 (ADAM10) expression in elderly patients with atherosclerotic acute myocardial infarction (AMI) and assess their prognostic value.
Methods: A retrospective analysis was conducted on 134 elderly patients with atherosclerotic AMI (disease group) and 110 healthy controls. Serum PDCD4 and ADAM10 levels were measured using ELISA. Based on prognosis, patients were divided into good prognosis (n=79) and poor prognosis groups (n=55). Clinical factors and biomarker levels were compared between groups. Logistic regression identified independent predictors of poor prognosis, and receiver operating characteristic (ROC) curves assessed predictive performance.
Results: Serum PDCD4 and ADAM10 levels were significantly higher in AMI patients compared with controls, and further elevated in the poor prognosis group (P< 0.05). Poor prognosis was also associated with older age, diabetes, STEMI, larger infarct size, anterior wall infarction, higher Killip class and GRACE score, elevated NT-proBNP and hs-CRP, and reduced LVEF (P< 0.05). Logistic regression confirmed elevated PDCD4 and ADAM10, diabetes, Killip class ≥II, GRACE score ≥ 140, STEMI, anterior infarction, NT-proBNP increase, and reduced LVEF as independent predictors of poor prognosis (P< 0.05). ROC analysis showed AUCs of 0.837 for PDCD4, 0.859 for ADAM10, and 0.931 for their combination, with the combined model outperforming either marker alone (P< 0.05).
Conclusion: Serum PDCD4 and ADAM10 are elevated in elderly atherosclerotic AMI patients and independently associated with poor prognosis. Combined detection may provide improved prognostic assessment, although further studies are warranted to validate these findings.
Keywords: PDCD4, ADAM10, elderly, atherosclerosis, acute myocardial infarction, prognosis